Phase 4 N=71 The 3DKnee™ System: A Post-Market Study
Osteoarthritis · Rheumatoid Arthritis · Post Traumatic Arthritis
Primary: Knee Society Score Evaluation — 82.9 Average Knee Rating Score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=386 Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) — 167.0; 168.2; 138.9; 151.6 mm Hg
Phase 4 N=20 Valproate in Late Life Schizophrenia
Schizophrenia
Primary: Change in Schizophrenia Psychopathology as Assessed by the Positive and Negative Symptom Scale (PANSS) — -17.45 scores on a scale — p=<0.001
Phase 4 N=437 A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome
Preterm Delivery
Primary: Composite Neonatal Morbidity < 34 Weeks Gestation at Time of Birth. — 71; 105 participants — p=0.002
Phase 4 N=306 Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination
Hepatitis B
Primary: Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations as Measured by ELISA Equal to or Above Cut-off Value — 266 Participants
Phase 4 N=941 Olmesartan Comparison to Losartan in Hypertensive Subjects
Hypertension
Primary: Change From Baseline to Week 8 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP) — -9.8; -9.7; -7.1 mmHg — p=<0.0001
Phase 4 N=305 Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients
Kidney Transplantation
Primary: Mean Percent Change in Glomerular Filtration Rate From Baseline to Month 12 — 59.5; 58.8; 24.4; 5.2 percent change — p=0.012
Phase 4 N=38 A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
Psoriasis
Primary: Psoriasis Area and Severity Index (PASI) 75 Response Rate at Week 10 — 71 Percentage of participants
Phase 4 N=17 Bronchodilator Responsiveness in Obliterative Bronchiolitis
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Phase 4 N=2,091 The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)
Diabetes Mellitus, Type 2
Primary: INITIATION: 24-Week Endpoint Glycosylated Hemoglobin (HbA1c) — 7.33; 7.23 percent glycosylated hemoglobin — p=0.005
Phase 4 N=3,650 Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td
Diphtheria · Tetanus
Primary: Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria. — 96; 97; 71; 71 Percentage of participants
Phase 4 N=70 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Acromegaly
Primary: The Percentage of Participants With Complete Response (CR) at 8 Months — 25; 0; 9.4 percent
Phase 4 N=19 Methotrexate Polyglutamate Levels as a Marker for the Clinical Outcome in the Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: DAS-28 (Disease Activity Score in 28 Joints) — 2.87; 2.66 Units on a Scale
Phase 4 N=31 United Kingdom User Evaluation, MiniMed Paradigm® X54 System
Diabetes Mellitus, Type 1
Primary: Usability of the X54 Insulin Pump Meets Expectations — 5.9 Scores on a scale
Phase 4 N=89 A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
Psoriasis
Primary: Proportion of Patients Who Achieved a ≥ 75% Decrease in Psoriasis Scalp Severity Index (PSSI) Score at 12 Weeks — 0.111; 0.274 Proportion of patients — p=0.1054